Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo | |
Su, Yongwei; Li, Xinyu; Ma, Jun; Zhao, Jianyun; Liu, Shuang; Wang, Guan; Edwards, Holly; Taub, Jeffrey W.; Lin, Hai; Ge, Yubin | |
刊名 | BIOCHEMICAL PHARMACOLOGY |
2018 | |
卷号 | 148 |
关键词 | Acute myeloid leukemia Pl3K mTOR ERK Bcl-2 |
ISSN号 | 0006-2952 |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3535185 |
专题 | 吉林大学白求恩第一医院 |
推荐引用方式 GB/T 7714 | Su, Yongwei,Li, Xinyu,Ma, Jun,et al. Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo[J]. BIOCHEMICAL PHARMACOLOGY,2018,148. |
APA | Su, Yongwei.,Li, Xinyu.,Ma, Jun.,Zhao, Jianyun.,Liu, Shuang.,...&Ge, Yubin.(2018).Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.BIOCHEMICAL PHARMACOLOGY,148. |
MLA | Su, Yongwei,et al."Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo".BIOCHEMICAL PHARMACOLOGY 148(2018). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论